nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—Stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.046	0.046	CcSEcCtD
Naltrexone—Pancreatitis acute—Cyclosporine—focal segmental glomerulosclerosis	0.0379	0.0379	CcSEcCtD
Naltrexone—Night sweats—Cyclosporine—focal segmental glomerulosclerosis	0.0324	0.0324	CcSEcCtD
Naltrexone—Hepatotoxicity—Cyclosporine—focal segmental glomerulosclerosis	0.0227	0.0227	CcSEcCtD
Naltrexone—Rigors—Cyclosporine—focal segmental glomerulosclerosis	0.0214	0.0214	CcSEcCtD
Naltrexone—Disturbance in attention—Cyclosporine—focal segmental glomerulosclerosis	0.0202	0.0202	CcSEcCtD
Naltrexone—Musculoskeletal stiffness—Cyclosporine—focal segmental glomerulosclerosis	0.0195	0.0195	CcSEcCtD
Naltrexone—Cellulitis—Cyclosporine—focal segmental glomerulosclerosis	0.0192	0.0192	CcSEcCtD
Naltrexone—Nightmare—Cyclosporine—focal segmental glomerulosclerosis	0.0169	0.0169	CcSEcCtD
Naltrexone—Mental disability—Cyclosporine—focal segmental glomerulosclerosis	0.0152	0.0152	CcSEcCtD
Naltrexone—Lymphadenopathy—Cyclosporine—focal segmental glomerulosclerosis	0.0149	0.0149	CcSEcCtD
Naltrexone—Gastroenteritis—Cyclosporine—focal segmental glomerulosclerosis	0.0143	0.0143	CcSEcCtD
Naltrexone—Disorientation—Cyclosporine—focal segmental glomerulosclerosis	0.0142	0.0142	CcSEcCtD
Naltrexone—Libido decreased—Cyclosporine—focal segmental glomerulosclerosis	0.0137	0.0137	CcSEcCtD
Naltrexone—Hot flush—Cyclosporine—focal segmental glomerulosclerosis	0.0136	0.0136	CcSEcCtD
Naltrexone—Increased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.0135	0.0135	CcSEcCtD
Naltrexone—Menopausal symptoms—Cyclosporine—focal segmental glomerulosclerosis	0.0135	0.0135	CcSEcCtD
Naltrexone—Purpura—Cyclosporine—focal segmental glomerulosclerosis	0.0132	0.0132	CcSEcCtD
Naltrexone—Arthritis—Cyclosporine—focal segmental glomerulosclerosis	0.0131	0.0131	CcSEcCtD
Naltrexone—Lethargy—Cyclosporine—focal segmental glomerulosclerosis	0.013	0.013	CcSEcCtD
Naltrexone—Disturbance in sexual arousal—Cyclosporine—focal segmental glomerulosclerosis	0.0126	0.0126	CcSEcCtD
Naltrexone—Migraine—Cyclosporine—focal segmental glomerulosclerosis	0.0125	0.0125	CcSEcCtD
Naltrexone—Abdominal pain upper—Cyclosporine—focal segmental glomerulosclerosis	0.0116	0.0116	CcSEcCtD
Naltrexone—Cramp muscle—Cyclosporine—focal segmental glomerulosclerosis	0.0114	0.0114	CcSEcCtD
Naltrexone—Sweating increased—Cyclosporine—focal segmental glomerulosclerosis	0.0107	0.0107	CcSEcCtD
Naltrexone—Bronchitis—Cyclosporine—focal segmental glomerulosclerosis	0.0106	0.0106	CcSEcCtD
Naltrexone—Abdominal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.0105	0.0105	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.0102	0.0102	CcSEcCtD
Naltrexone—Weight increased—Cyclosporine—focal segmental glomerulosclerosis	0.00999	0.00999	CcSEcCtD
Naltrexone—Weight decreased—Cyclosporine—focal segmental glomerulosclerosis	0.00993	0.00993	CcSEcCtD
Naltrexone—Pneumonia—Cyclosporine—focal segmental glomerulosclerosis	0.00984	0.00984	CcSEcCtD
Naltrexone—Infestation NOS—Cyclosporine—focal segmental glomerulosclerosis	0.00979	0.00979	CcSEcCtD
Naltrexone—Infestation—Cyclosporine—focal segmental glomerulosclerosis	0.00979	0.00979	CcSEcCtD
Naltrexone—Depression—Cyclosporine—focal segmental glomerulosclerosis	0.00976	0.00976	CcSEcCtD
Naltrexone—Acute coronary syndrome—Cyclosporine—focal segmental glomerulosclerosis	0.00965	0.00965	CcSEcCtD
Naltrexone—Myocardial infarction—Cyclosporine—focal segmental glomerulosclerosis	0.00959	0.00959	CcSEcCtD
Naltrexone—Urinary tract infection—Cyclosporine—focal segmental glomerulosclerosis	0.00951	0.00951	CcSEcCtD
Naltrexone—Conjunctivitis—Cyclosporine—focal segmental glomerulosclerosis	0.00951	0.00951	CcSEcCtD
Naltrexone—Hepatobiliary disease—Cyclosporine—focal segmental glomerulosclerosis	0.00926	0.00926	CcSEcCtD
Naltrexone—Epistaxis—Cyclosporine—focal segmental glomerulosclerosis	0.00923	0.00923	CcSEcCtD
Naltrexone—Sinusitis—Cyclosporine—focal segmental glomerulosclerosis	0.00918	0.00918	CcSEcCtD
Naltrexone—Hepatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00879	0.00879	CcSEcCtD
Naltrexone—Pharyngitis—Cyclosporine—focal segmental glomerulosclerosis	0.00872	0.00872	CcSEcCtD
Naltrexone—Connective tissue disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00863	0.00863	CcSEcCtD
Naltrexone—Tinnitus—Cyclosporine—focal segmental glomerulosclerosis	0.00819	0.00819	CcSEcCtD
Naltrexone—Angiopathy—Cyclosporine—focal segmental glomerulosclerosis	0.00797	0.00797	CcSEcCtD
Naltrexone—Mediastinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00792	0.00792	CcSEcCtD
Naltrexone—Chills—Cyclosporine—focal segmental glomerulosclerosis	0.00788	0.00788	CcSEcCtD
Naltrexone—Alopecia—Cyclosporine—focal segmental glomerulosclerosis	0.00776	0.00776	CcSEcCtD
Naltrexone—Mental disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0077	0.0077	CcSEcCtD
Naltrexone—Malnutrition—Cyclosporine—focal segmental glomerulosclerosis	0.00765	0.00765	CcSEcCtD
Naltrexone—Flatulence—Cyclosporine—focal segmental glomerulosclerosis	0.00754	0.00754	CcSEcCtD
Naltrexone—Tension—Cyclosporine—focal segmental glomerulosclerosis	0.00751	0.00751	CcSEcCtD
Naltrexone—Dysgeusia—Cyclosporine—focal segmental glomerulosclerosis	0.00749	0.00749	CcSEcCtD
Naltrexone—Nervousness—Cyclosporine—focal segmental glomerulosclerosis	0.00743	0.00743	CcSEcCtD
Naltrexone—Muscle spasms—Cyclosporine—focal segmental glomerulosclerosis	0.00735	0.00735	CcSEcCtD
Naltrexone—Vision blurred—Cyclosporine—focal segmental glomerulosclerosis	0.00721	0.00721	CcSEcCtD
Naltrexone—Tremor—Cyclosporine—focal segmental glomerulosclerosis	0.00717	0.00717	CcSEcCtD
Naltrexone—Ill-defined disorder—Cyclosporine—focal segmental glomerulosclerosis	0.0071	0.0071	CcSEcCtD
Naltrexone—Agitation—Cyclosporine—focal segmental glomerulosclerosis	0.00703	0.00703	CcSEcCtD
Naltrexone—Angioedema—Cyclosporine—focal segmental glomerulosclerosis	0.00699	0.00699	CcSEcCtD
Naltrexone—Malaise—Cyclosporine—focal segmental glomerulosclerosis	0.0069	0.0069	CcSEcCtD
Naltrexone—Cough—Cyclosporine—focal segmental glomerulosclerosis	0.00667	0.00667	CcSEcCtD
Naltrexone—Convulsion—Cyclosporine—focal segmental glomerulosclerosis	0.00663	0.00663	CcSEcCtD
Naltrexone—Hypertension—Cyclosporine—focal segmental glomerulosclerosis	0.0066	0.0066	CcSEcCtD
Naltrexone—Chest pain—Cyclosporine—focal segmental glomerulosclerosis	0.00651	0.00651	CcSEcCtD
Naltrexone—Myalgia—Cyclosporine—focal segmental glomerulosclerosis	0.00651	0.00651	CcSEcCtD
Naltrexone—Arthralgia—Cyclosporine—focal segmental glomerulosclerosis	0.00651	0.00651	CcSEcCtD
Naltrexone—Anxiety—Cyclosporine—focal segmental glomerulosclerosis	0.00649	0.00649	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—focal segmental glomerulosclerosis	0.00647	0.00647	CcSEcCtD
Naltrexone—Discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00643	0.00643	CcSEcCtD
Naltrexone—Dry mouth—Cyclosporine—focal segmental glomerulosclerosis	0.00637	0.00637	CcSEcCtD
Naltrexone—Confusional state—Cyclosporine—focal segmental glomerulosclerosis	0.00629	0.00629	CcSEcCtD
Naltrexone—Anaphylactic shock—Cyclosporine—focal segmental glomerulosclerosis	0.00624	0.00624	CcSEcCtD
Naltrexone—Oedema—Cyclosporine—focal segmental glomerulosclerosis	0.00624	0.00624	CcSEcCtD
Naltrexone—Infection—Cyclosporine—focal segmental glomerulosclerosis	0.0062	0.0062	CcSEcCtD
Naltrexone—Nervous system disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00612	0.00612	CcSEcCtD
Naltrexone—Skin disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00606	0.00606	CcSEcCtD
Naltrexone—Hyperhidrosis—Cyclosporine—focal segmental glomerulosclerosis	0.00603	0.00603	CcSEcCtD
Naltrexone—Anorexia—Cyclosporine—focal segmental glomerulosclerosis	0.00595	0.00595	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Cyclosporine—focal segmental glomerulosclerosis	0.00569	0.00569	CcSEcCtD
Naltrexone—Insomnia—Cyclosporine—focal segmental glomerulosclerosis	0.00565	0.00565	CcSEcCtD
Naltrexone—Paraesthesia—Cyclosporine—focal segmental glomerulosclerosis	0.00561	0.00561	CcSEcCtD
Naltrexone—Dyspnoea—Cyclosporine—focal segmental glomerulosclerosis	0.00557	0.00557	CcSEcCtD
Naltrexone—Somnolence—Cyclosporine—focal segmental glomerulosclerosis	0.00555	0.00555	CcSEcCtD
Naltrexone—Decreased appetite—Cyclosporine—focal segmental glomerulosclerosis	0.00543	0.00543	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Cyclosporine—focal segmental glomerulosclerosis	0.00539	0.00539	CcSEcCtD
Naltrexone—Fatigue—Cyclosporine—focal segmental glomerulosclerosis	0.00538	0.00538	CcSEcCtD
Naltrexone—Constipation—Cyclosporine—focal segmental glomerulosclerosis	0.00534	0.00534	CcSEcCtD
Naltrexone—Pain—Cyclosporine—focal segmental glomerulosclerosis	0.00534	0.00534	CcSEcCtD
Naltrexone—Feeling abnormal—Cyclosporine—focal segmental glomerulosclerosis	0.00514	0.00514	CcSEcCtD
Naltrexone—Gastrointestinal pain—Cyclosporine—focal segmental glomerulosclerosis	0.0051	0.0051	CcSEcCtD
Naltrexone—Urticaria—Cyclosporine—focal segmental glomerulosclerosis	0.00496	0.00496	CcSEcCtD
Naltrexone—Abdominal pain—Cyclosporine—focal segmental glomerulosclerosis	0.00493	0.00493	CcSEcCtD
Naltrexone—Body temperature increased—Cyclosporine—focal segmental glomerulosclerosis	0.00493	0.00493	CcSEcCtD
Naltrexone—Hypersensitivity—Cyclosporine—focal segmental glomerulosclerosis	0.0046	0.0046	CcSEcCtD
Naltrexone—Asthenia—Cyclosporine—focal segmental glomerulosclerosis	0.00448	0.00448	CcSEcCtD
Naltrexone—Pruritus—Cyclosporine—focal segmental glomerulosclerosis	0.00442	0.00442	CcSEcCtD
Naltrexone—Diarrhoea—Cyclosporine—focal segmental glomerulosclerosis	0.00427	0.00427	CcSEcCtD
Naltrexone—Dizziness—Cyclosporine—focal segmental glomerulosclerosis	0.00413	0.00413	CcSEcCtD
Naltrexone—Vomiting—Cyclosporine—focal segmental glomerulosclerosis	0.00397	0.00397	CcSEcCtD
Naltrexone—Rash—Cyclosporine—focal segmental glomerulosclerosis	0.00394	0.00394	CcSEcCtD
Naltrexone—Dermatitis—Cyclosporine—focal segmental glomerulosclerosis	0.00393	0.00393	CcSEcCtD
Naltrexone—Headache—Cyclosporine—focal segmental glomerulosclerosis	0.00391	0.00391	CcSEcCtD
Naltrexone—Nausea—Cyclosporine—focal segmental glomerulosclerosis	0.00371	0.00371	CcSEcCtD
